TScan Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The conference highlighted a differentiated TCR T cell therapy platform targeting post-transplant AML/MDS relapse, with phase I data showing >50% relapse reduction and long-lived responses. A pivotal trial launches mid-2024, with commercial launch expected in 2029 and strong profit margins projected. Additional HLA-targeted products and an in vivo solid tumor platform are in development.
-
Lead TCR T-cell therapy for heme malignancies shows strong phase I efficacy and safety, with pivotal trial launching in Q2 and commercial-ready manufacturing in place. Market expansion through additional HLA-targeted products could double the addressable patient population.
Fiscal Year 2025
-
Updated data show TSC-101 delivers strong efficacy and safety in high-risk AML/MDS post-transplant patients, with a new commercial-ready process improving scalability and cost. The pivotal trial is set for Q2 next year, with plans to expand the addressable market through additional HLA-targeted products.
-
Lead heme malignancy program shows 82% relapse-free rate and is moving to a pivotal trial in Q2 next year. Solid tumor efforts pivot to in vivo engineering, and autoimmunity research advances with new target discoveries. Cash runway now extends into the second half of 2027.
-
FDA agreed to additional high-dose patient data collection before pivotal trial launch in Q2 2026. A new manufacturing process improves efficiency and is expected to enhance efficacy. Strategic focus shifts to the HEME program, with solid tumor efforts moving to in vivo engineering.
-
Lead heme malignancy program demonstrated a significant reduction in relapse rates, supporting a pivotal trial launch this year. Market expansion is underway through new HLA-targeted TCRs, while multiplex solid tumor and autoimmunity programs are advancing, with key data readouts expected by early next year.
-
TCR-T cell therapy programs show promising early results in reducing relapse rates for hematologic malignancies, with a pivotal trial launching this year and expansion to new HLA types underway. Multiplex TCR therapy for solid tumors is advancing, with key safety and efficacy data expected in Q1 next year.
-
Two clinical programs are advancing: a heme malignancy therapy with strong early results and a solid tumor multiplex TCR approach. A pivotal heme trial launches in H2 2024, with key data updates for both programs expected by year-end.
-
A sequential IL-17/IL-23 therapy aims to optimize psoriasis treatment, with key Phase I and II data expected over the next year. Strong funding supports clinical progress, and half-life benchmarks are set to enable less frequent dosing.
-
The company is advancing TCR-engineered T cell therapies for heme and solid tumors, with pivotal trials and first efficacy data expected in the next 12–18 months. Manufacturing and regulatory processes are optimized, and financial runway extends into Q1 2027.
-
Two main programs are advancing: a heme malignancy therapy with pivotal trial launch in H2 2024 and a solid tumor multiplex TCR program aiming for deeper responses. Key 2024 milestones include pivotal trial initiation, long-term heme data, and multiplex solid tumor updates.
-
The conference highlighted significant progress in TCR-T therapies for both hematologic and solid tumors, with strong early clinical results and a pivotal trial set to launch in H2 2024. Multiplex therapy for solid tumors is advancing, with key efficacy and safety updates expected by year-end.
Fiscal Year 2024
-
TCR-T therapies TSC100/101 showed strong efficacy and safety in high-risk post-transplant patients, leading to FDA RMAT designation and a pivotal trial focused on TSC101. The addressable market could expand significantly, and a solid tumor program is advancing with multiplex TCR-T therapies.
-
A next-generation TCR-T therapy platform is advancing in both hematologic and solid tumors, with early clinical data showing relapse-free outcomes in high-risk blood cancer patients and a customizable multiplex approach for solid tumors. Expansion of the ImmunoBank and multiplex therapy is expected to broaden patient eligibility and market reach.
-
The platform enables rapid TCR discovery and manufacturing for both liquid and solid tumors, with strong early efficacy and safety data in AML/MDS and a multiplex approach for solid tumors. Pivotal trials are planned, and the company is well-funded through 2026.